Dennis  Matheis net worth and biography

Dennis Matheis Biography and Net Worth

Director of Lucid Diagnostics

Dennis Matheis brings over three decades of experience in healthcare industry leadership, including in healthcare delivery and health insurance across large national and regional health plans. Mr. Matheis currently serves as the President and Chief Executive Officer of Virginia-based Sentara Health, one of the twenty largest not-for-profit integrated health systems in the country with nearly $13 billion in annual revenue and over 32,000 employees. Sentara encompasses twelve acute care hospitals in the Mid-Atlantic region with over 120,000 admissions per year, a medical group with over 1,500 clinicians and more than 2.8 million patient visits per year, and an affiliated health plan, Sentara Health Plans (SHP), with over one million covered lives. Before becoming CEO, he was the Executive Vice President of Sentara and the President of SHP. Prior to joining Sentara, Mr. Matheis spent 13 years in leadership roles at Anthem, Inc., one of the largest health insurance plans in the United States. He served as President of Anthem's Central Region and Exchanges encompassing six states and representing $12 billion in annual revenue. Mr. Matheis previously served in senior leadership roles at Anthem Blue Cross and Blue Shield of Missouri, CIGNA Healthcare and Humana Health Plan, as well as Advocate Health Care in Chicago.

Mr. Matheis earned his Bachelor of Science degree in Accounting from the University of Kentucky and practiced as a Certified Public Accountant before entering the healthcare industry. He serves as Co-Chair of the Hampton Roads Executive Roundtable. He also serves on the Board of Directors of the Virginia Chamber of Commerce – Team Virginia, DarioHealth (Nasdaq: DRIO), and on the Board of Directors and Executive Committee of America's Health Insurance Plans (AHIP).

What is Dennis Matheis' net worth?

The estimated net worth of Dennis Matheis is at least $1.23 million as of May 20th, 2026. Mr. Matheis owns 1,033,443 shares of Lucid Diagnostics stock worth more than $1,234,964 as of July 15th. This net worth evaluation does not reflect any other investments that Mr. Matheis may own. Learn More about Dennis Matheis' net worth.

How do I contact Dennis Matheis?

The corporate mailing address for Mr. Matheis and other Lucid Diagnostics executives is , , . Lucid Diagnostics can also be reached via phone at 212-949-4319 and via email at [email protected]. Learn More on Dennis Matheis' contact information.

Has Dennis Matheis been buying or selling shares of Lucid Diagnostics?

Dennis Matheis has not been actively trading shares of Lucid Diagnostics during the last ninety days. Most recently, on Wednesday, May 20th, Dennis Matheis bought 245,000 shares of Lucid Diagnostics stock. The stock was acquired at an average cost of $1.00 per share, with a total value of $245,000.00. Following the completion of the transaction, the director now directly owns 1,033,443 shares of the company's stock, valued at $1,033,443. Learn More on Dennis Matheis' trading history.

Are insiders buying or selling shares of Lucid Diagnostics?

In the last year, Lucid Diagnostics insiders bought shares 2 times. They purchased a total of 345,000 shares worth more than $347,000.00. The most recent insider tranaction occured on May, 20th when Director Dennis Matheis bought 245,000 shares worth more than $245,000.00. Insiders at Lucid Diagnostics own 6.9% of the company. Learn More about insider trades at Lucid Diagnostics.

Information on this page was last updated on 5/20/2026.

Dennis Matheis Insider Trading History at Lucid Diagnostics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/20/2026Buy245,000$1.00$245,000.001,033,443View SEC Filing Icon  
8/20/2025Buy100,000$1.02$102,000.00665,443View SEC Filing Icon  
See Full Table

Dennis Matheis Buying and Selling Activity at Lucid Diagnostics

This chart shows Dennis Matheis's buying and selling at Lucid Diagnostics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lucid Diagnostics Company Overview

Lucid Diagnostics logo
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Read More

Today's Range

Now: $1.15
Low: $1.00
High: $1.23

50 Day Range

MA: $1.02
Low: $0.95
High: $1.11

2 Week Range

Now: $1.15
Low: $0.90
High: $1.63

Volume

5,168,717 shs

Average Volume

1,261,620 shs

Market Capitalization

$233.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07